Signals, Powered By EquityPandit
Suven Life Sciences has received product patents in India and South Korea. These patents are valid through 2029 and 2033 respectively.
The company in its filing stated, “..announces that the grant of one product patent from India and one product patent from South Korea corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.”
Further, these patents include the class of selective Alpha4 Beta2 and 5-HT4 compounds respectively and are being developed as therapeutic agents for depressive disorders and for treatment of cognitive impairment related to neurodegenerative disorders.
